乔桐杉, 周雯敏, 范欣悦, 张雨荃, 谢婷, 林晓琪, 乔山, 郝利恒, 王猛, 张建业. 酯蟾毒配基抑制人肝癌细胞体外增殖和迁移侵袭研究J. 药学学报, 2022,57(7): 2101-2107. doi: 10.16438/j.0513-4870.2022-0119
引用本文: 乔桐杉, 周雯敏, 范欣悦, 张雨荃, 谢婷, 林晓琪, 乔山, 郝利恒, 王猛, 张建业. 酯蟾毒配基抑制人肝癌细胞体外增殖和迁移侵袭研究J. 药学学报, 2022,57(7): 2101-2107. doi: 10.16438/j.0513-4870.2022-0119
QIAO Tong-shan, ZHOU Wen-min, FAN Xin-yue, ZHANG Yu-quan, XIE Ting, LIN Xiao-qi, QIAO Shan, HAO Li-heng, WANG Meng, ZHANG Jian-ye. Resibufogenin suppresses human hepatocellular carcinoma cell proliferation, migration and invasion in vitroJ. Acta Pharmaceutica Sinica, 2022,57(7): 2101-2107. doi: 10.16438/j.0513-4870.2022-0119
Citation: QIAO Tong-shan, ZHOU Wen-min, FAN Xin-yue, ZHANG Yu-quan, XIE Ting, LIN Xiao-qi, QIAO Shan, HAO Li-heng, WANG Meng, ZHANG Jian-ye. Resibufogenin suppresses human hepatocellular carcinoma cell proliferation, migration and invasion in vitroJ. Acta Pharmaceutica Sinica, 2022,57(7): 2101-2107. doi: 10.16438/j.0513-4870.2022-0119

酯蟾毒配基抑制人肝癌细胞体外增殖和迁移侵袭研究

Resibufogenin suppresses human hepatocellular carcinoma cell proliferation, migration and invasion in vitro

  • 摘要: 本文旨在探讨酯蟾毒配基对人肝癌细胞增殖和迁移侵袭的影响及其相关机制。采用MTT比色法测定酯蟾毒配基对4种肝癌细胞的体外生长抑制作用,划痕实验和Transwell实验用来评估酯蟾毒配基对MHCC-97H细胞的迁移和侵袭能力,采用Western blot实验检测经不同浓度酯蟾毒配基处理后,MHCC-97H细胞内迁移侵袭相关蛋白的表达。结果表明,酯蟾毒配基能明显抑制肝癌细胞的体外增殖能力,其对MHCC-97H、HepG2、SK-Hep-1、Huh-7细胞的半数抑制浓度(half maximal inhibitory concentration,IC50)值分别为0.55 ±0.06、2.83 ±0.24、5.25 ±0.49、14.89 ±2.28 μmol·L-1;酯蟾毒配基还能显著抑制MHCC-97H细胞的迁移和侵袭能力,且具有显著的浓度依赖性。MHCC-97H细胞中的整合素α2(integrin α2)、整合素α6(integrin α6)、整合素β1(integrin β1)、N-钙黏蛋白(N-cadherin)、基质金属蛋白酶2(matrix metalloproteinase 2,MMP2)、转录因子Twist的蛋白表达随着酯蟾毒配基的浓度增加而明显降低,而E-钙黏蛋白(E-cadherin)蛋白表达升高。此外,研究发现酯蟾毒配基作用细胞后p-PI3K/PI3K和p-AKT/AKT比值显著降低。综上所述,酯蟾毒配基明显抑制肝癌MHCC-97H细胞的体外增殖和迁移侵袭能力,与调控细胞内迁移侵袭蛋白表达及PI3K/AKT信号通路相关。

     

    Abstract: This manuscript aims to investigate the effects of resibufogenin on the proliferation, migration and invasion of human hepatocellular carcinoma cells and its related mechanisms. MTT assay was used to determine the inhibitory effect of resibufogenin on the growth of four hepatocellular carcinoma cells in vitro. Wound-healing assay and Transwell assay were used to evaluate the migration and invasion ability of resibufogenin on MHCC-97H cells. Western blot assay was used to detect the expression of migration and invasion related proteins in MHCC-97H cells treated with different concentrations of resibufogenin. The results showed that resibufogenin significantly inhibited the proliferation of hepatocellular carcinoma cells in vitro. The half maximal inhibitory concentration (IC50) values on MHCC-97H, HepG2, SK-Hep-1 and Huh-7 cells were 0.55 ±0.06, 2.83 ±0.24, 5.25 ±0.49, 14.89 ±2.28 μmol·L-1, respectively. Resibufogenin also suppressed the migration and invasion of MHCC-97H cells in a concentration-dependent manner. The protein expression of integrin α2, integrin α6, integrin β1, N-cadherin, matrix metalloproteinase 2 (MMP2) and transcription factor Twist in MHCC-97H cells were decreased significantly with the increase of the concentration of resibufogenin, while the protein expression of E-cadherin increased. In addition, we found that p-PI3K/PI3K and p-AKT/AKT ratios were significantly reduced after treatment with resibufogenin. In conclusion, resibufogenin can inhibit the proliferation, migration and invasion of hepatocellular carcinoma MHCC-97H cells in vitro, which is related to the regulation of intracellular migration and invasion protein expression and PI3K/AKT signaling pathway.

     

/

返回文章
返回